Newsroom & Press Releases

VisionGate Announces an Exclusive Global License, Manufacturing and Supply Agreement for Iloprost, VisionGate’s Phase 2 Oral Lung Cancer Interception Drug
Press Release, August 22, 2019

VisionGate Announces Lung Cancer Prevention Trial Progress and PCI Pharma Services Manufacturing Agreement
Press Release, January 29, 2019

VisionGate, Inc. Appoints R. John Glasspool as Chief Operating and Strategy Officer and member of the Board of Directors
Press Release, October 11, 2018

VisionGate Announces the Results and Presentation of Important New Research at the 2018 IASLC World Conference on Lung Cancer (WCLC), Toronto, Canada.
Press Release, September 24, 2018

VisionGate Announces New Appointment to the Board of Directors
Press Release, June 14, 2018

VisionGate, Inc. Appoints Randal Buness as Chief Financial Officer
Press Release, April 17, 2018

VisionGate’s Cell-CT™ 3D Cellular Imaging Platform Detects the Presence of Cancer-Associated Cells (CACs) that have undergone Malignancy Associated Change (MAC)
Press Release, April 16, 2018

VisionGate Lung Cancer 3D Cellular Imaging Research to be Featured as a Late-Breaking Abstract at the AACR Annual Meeting 2018
Press Release, April 12, 2018

VisionGate is Leveraging the Cell-CT™ Platform to Expand Cancer Diagnostics Services, Biopharmaceutical Services and Cancer Prevention Medicines
Press Release, April 5, 2018

VisionGate Announces Two New Appointments to the Board of Directors; Biotech Experienced Directors Further Strengthen the Company Leadership
Press Release, April 4, 2018

New Research Study Demonstrates Applicability of VisionGate’s 3-Dimensional Cell-CT™ Imaging and Analysis Platform
Press Release, December 12, 2017

VisionGate® Showcases Advances in Lung Cancer Early Detection and Treatment at the World Conference on Lung Cancer
Press Release, October 19, 2017

VisionGate Hires Prominent Pathologist as Medical Director, VisionGate, Inc.
Press Release, June 7, 2017

Related Pages

This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. Forward-looking statements are based on estimates, projections, beliefs and assumptions of VisionGate® management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice.

Contact Us

If you are interested in learning more about VisionGate and would like to speak with someone, please complete this short inquiry form and a representative will contact you as soon as possible.

Copyright 2020 - VisionGate, Inc.